MODEL PREDICTIONS FOR LIFETIME HEALTH BENEFITS OF MOBOCERTINIB AND CURRENT TREATMENT OPTIONS IN POST-PLATINUM PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC HARBORING EGFR EXON 20 INSERTION MUTATION IN CHINA

被引：0
|
作者：
Zuo, G. Y. [1 ]
Wang, Y. [2 ]
Gao, Y. [3 ]
Zhang, Y. J. [3 ]
Zhu, F. F. [3 ]
机构：
[1] Shandong Univ, Jinan, Peoples R China
[2] Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R China
[3] Takeda China Int Trading Co, Beijing, Peoples R China
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
CO214
引用
收藏
页码：S55 / S56
页数：2
相关论文
共 17 条
  • [1] Amivantamab-Vmjw: A Novel Treatment for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutation after Progression on Platinum-Based Chemotherapy
    Shah, Vishal
    McNatty, Andrea
    Simpson, Lacey
    Ofori, Henry
    Raheem, Farah
    BIOMEDICINES, 2023, 11 (03)
  • [2] Mobocertinib in Platinum-Pretreated EGFR Exon 20 Insertion+ Metastatic NSCLC Patients With/Without Prior Anti-PD(L)-1 Therapy
    Janne, P.
    Ramalingam, S.
    Kim, T.
    Yang, J. C.
    Riely, G.
    Mekhail, T.
    Nguyen, D.
    Garcia Campelo, M. R.
    Felip, E.
    Jin, S.
    Griffin, C.
    Bunn, V.
    Lin, J.
    Mehta, M.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S960 - S960
  • [3] Treatment Patterns and Clinical Outcomes among Advanced NSCLC Patients with EGFR exon 20 Insertion Mutations in China
    Wang, Y.
    Lin, H. M.
    Ning, N.
    Du, F.
    Gao, X.
    Dong, Q.
    Yang, G.
    Xu, H.
    He, Y.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S609 - S609
  • [4] Real-World Treatment Patterns of Patients with EGFR Exon 20 Insertion-Mutated Advanced NSCLC Treated with Amivantamab or Mobocertinib after Platinum-Based Chemotherapy
    Spira, Alexander
    Waters, Dexter
    Ran, Tao
    Vadagam, Pratyusha
    He, Jinghua
    Vanderpoel, Julie
    Donnelly, Anjali
    Lin, Iris
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E32 - E32
  • [5] Phase I/II study of mobocertinib in EGFR exon 20 insertion (ex20ins) + metastatic NSCLC (mNSCLC): Updated results from platinum-pretreated patients (PPP)
    Ramalingam, S. S.
    Zhou, C.
    Kim, T. M.
    Yang, J. C-H.
    Riely, G. J.
    Mekhail, T.
    Nguyen, D.
    Garcia Campelo, M. R.
    Felip, E.
    Misch, D.
    Kaur, M.
    Bunn, V.
    Lin, M.
    Zhang, P.
    Janne, P. A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1004 - S1004
  • [6] EXCLAIM-2: Phase III trial of first-line (1L) mobocertinib versus platinum-based chemotherapy in patients (pts) with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)+ locally advanced/ metastatic NSCLC
    Janne, P. A.
    Wang, B-C.
    Cho, B. C.
    Zhao, J.
    Li, J.
    Hochmair, M. J.
    Peters, S.
    Besse, B.
    Kato, T.
    Wu, Y-L.
    Nguyen, D.
    Lin, J.
    Lin, J.
    Vranceanu, F.
    Lin, M.
    Fram, R. J.
    Mok, T. S. K.
    ANNALS OF ONCOLOGY, 2023, 34 : S1663 - S1664
  • [7] EGFR exon 20 insertion mutations in patients with locally advanced or metastatic NSCLC in the German prospective, CRISP Registry real-world cohort (AIO-TRK-0315)
    Griesinger, F.
    Sebastian, M.
    Bethge, A.
    Christopoulos, P.
    Hoffknecht, P.
    Waller, C.
    Benkelmann, R.
    Jaenicke, M.
    Fleitz, A.
    Hanselmann, J.
    Hipper, A.
    Groth, A.
    Weichert, W.
    Nusch, A.
    Rauh, J.
    Fietz, T.
    Illmer, T.
    Depenbusch, R.
    Eberhardt, W. E. E.
    Thomas, M.
    ANNALS OF ONCOLOGY, 2022, 33 : S54 - S55
  • [8] Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK-029A in Treatment-Naive Patients With Advanced NSCLC Harboring EGFR EXon 20 Insertion Mutations: A Phase 1 Trial
    Duan, Jianchun
    Wu, Lin
    Yang, Kunyu
    Zhao, Jun
    Zhao, Yanqiu
    Dai, Xiumei
    Li, Mingjun
    Xie, Yanyan
    Yao, Yu
    Zhao, Mingfang
    Zhou, Chengzhi
    Ren, Xiubao
    Liu, Zhe
    Pan, Yueyin
    Li, Yuping
    Liu, Baogang
    Cheng, Ying
    Miao, Liyun
    Yu, Qitao
    Zhang, Zhihong
    Liu, Xiaoqing
    Cui, Jiuwei
    Zhang, Yu
    Zhang, Li
    Li, Xiaoyan
    Li, Xiaoling
    Shen, Bo
    Chen, Bi
    Zeng, Shan
    Li, Bin
    Hu, Yanping
    Li, Lin
    Wu, Rong
    Song, Qibin
    Wang, Jie
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (02) : 314 - 324
  • [9] Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Additional results from platinum-pretreated patients (pts) and EXCLAIM cohort of phase 1/2 study.
    Ramalingam, Suresh S.
    Zhou, Caicun
    Kim, Tae Min
    Kim, Sang-We
    Yang, James Chih-Hsin
    Riely, Gregory J.
    Mekhail, Tarek
    Nguyen, Danny
    Campelo, Maria Rosario Garcia
    Felip, Enriqueta
    Vincent, Sylvie
    Jin, Shu
    Bunn, Veronica
    Lin, Jianchang
    Lin, Huamao Mark
    Mehta, Minal
    Janne, Pasi A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm open-label, multicentre, phase 2 trial
    Wang, Mengzhao
    Fan, Yun
    Sun, Meili
    Wang, Yongsheng
    Zhao, Yanqiu
    Jin, Bo
    Hu, Ying
    Han, Zhigang
    Song, Xia
    Liu, Anwen
    Tang, Kejing
    Ding, Cuimin
    Liang, Li
    Wu, Lin
    Gao, Junzhen
    Wang, Jianghong
    Cheng, Ying
    Zhou, Jianying
    He, Yong
    Dong, Xiaorong
    Yao, Yu
    Yu, Yan
    Wang, Huijie
    Sun, Si
    Huang, Jianan
    Fang, Jian
    Li, Wen
    Wang, Lin
    Ren, Xiubao
    Zhou, Chengzhi
    Hu, Yanping
    Zhao, Dahai
    Yang, Runxiang
    Xu, Fei
    Huang, Yijiang
    Pan, Yueyin
    Cui, Jiuwei
    Xu, Yan
    Yang, Zhenfan
    Shi, Yuankai
    LANCET RESPIRATORY MEDICINE, 2024, 12 (03): : 217 - 224
12